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OBJECTIVES To evaluate whether oral folic acid supplementation might improve endothelial function in
the arteries of asymptomatic adults with hyperhomocystinemia.
BACKGROUND Hyperhomocystinemia is an independent risk factor for endothelial dysfunction and occlusive
vascular disease. Folic acid supplementation can lower homocystine levels in subjects with
hyperhomocystinemia; however, the effect of this on arterial physiology is not known.
METHODS Adults subjects were recruited from a community-based atherosclerosis study on healthy
volunteers aged 40 to 70 years who had no history of hypertension, diabetes mellitus,
hyperlipidemia, ischemic heart disease or family history of premature atherosclerosis (n 5 89).
Seventeen subjects (aged 54 6 10 years, 15 male) with fasting total homocystine levels above
75th percentile (mean, 9.8 6 2.8 mmol/liter) consented to participate in a double-blind,
randomized, placebo-controlled and crossover trial; each subject received oral folic acid
(10 mg/day) and placebo for 8 weeks, each separated by a washout period of four weeks.
Flow-mediated endothelium-dependent dilation (percent increase in diameter) of the brachial
artery was assessed by high resolution ultrasound, before and after folic acid or placebo
supplementation.
RESULTS Compared with placebo, folic acid supplementation resulted in higher serum folate levels
(66.2 6 7.0 vs. 29.7 6 14.8 nmol/liter; p , 0.001), lower total plasma homocystine levels
(8.1 6 3.1 vs. 9.5 6 2.5 mmol/liter, p 5 0.03) and significant improvement in endothelium-
dependent dilation (8.2 6 1.6% vs. 6 6 1.3%, p , 0.001). Endothelium-independent
responses to nitroglycerin were unchanged. No adverse events were observed.
CONCLUSION Folic acid supplementation improves arterial endothelial function in adults with relative
hyperhomocystinemia, with potentially beneficial effects on the atherosclerotic process.
(J Am Coll Cardiol 1999;34:2002–6) © 1999 by the American College of Cardiology
Recent epidemiologic studies have demonstrated a clear
association between hyperhomocystinemia (HHC) and pre-
mature coronary, cerebral and peripheral vascular disease
(1,2). HHC is found in approximately one in three subjects
with premature coronary artery disease and is therefore
considered a common as well as an independent risk factor
for occlusive vascular disease (1). Homocystine (Hcy) is a
highly reactive amino acid, damaging to arterial endothelial
cells in both cell culture and experimental animal studies
(3,4), and recently we (5) and others have demonstrated
impaired arterial endothelial function in otherwise healthy
adults with HHC (6) or homocystine levels at upper
physiologic range (7).
Folic acid is a naturally occurring nutritional element that
reduces homocystine levels by increasing the rate of recy-
cling of homocystine to methionine (2). It is unknown,
however, whether oral folic acid supplements can modify
vascular disease in subjects with HHC. As arterial endothe-
lial dysfunction is an important early event in atherogenesis
(8), we assessed the effect of folic acid on endothelial
physiology in adults with HHC, in a double-blind, random-
ized, placebo-controlled study.
METHODS
Subjects. Adult subjects were recruited from a community-
based atherosclerosis study carried out in Hong Kong on
healthy volunteers aged 40 to 70 years who had no history
of hypertension, diabetes mellitus, hyperlipidemia, ischemic
heart disease or family history of premature atherosclerosis
(5). None were taking any cardiovascular medications.
HHC was defined as fasting total plasma Hcy (tHcy) above
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the 75th percentile for the 89 subjects studied to date; of the
22 adults approached, 17 gave informed consent and par-
ticipated in the folic acid trial. None had been taking
multivitamin supplements in the 12 months before enroll-
ment. This study was approved by the institutional ethics
committee.
Study design. After enrollment, each subject was random-
ized to receive either oral folic acid (10 mg/day) or placebo
for eight weeks, in a double-blind fashion, followed by a
“washout” period of four weeks, then crossed over to either
placebo or folic acid for the final eight weeks. A 10-mg oral
daily dose of folic acid is known to be safe and was chosen
to maximize the Hcy-lowering effect within the time frame
of the study. Subjects were reviewed at the end of each
eight-week treatment period (but not after the washout
phase). On each occasion, subjects attended after a 14-h fast
(except for the study medication) for a blood test, measure-
ment of resting supine blood pressure and an arterial
ultrasound study (as described below). Ultrasound studies
were analyzed by an observer “blinded” in every case to
subject identity and to the stage of the experiment, as
previously reported (9).
Methods. At baseline study, venous blood from fasting
subjects was assayed for total cholesterol, triglycerides,
HDL-cholesterol, glucose and creatinine levels by standard
techniques. At baseline and also after each of the eight-week
treatment periods, vitamin B12 and folate levels in serum
were measured by immunoassay (DPC dual count solid-
phase no-boil kits), with the upper limit measured being
85.8 nmol/liter by serial dilution, and total homocystine
levels assessed on frozen stored samples by enzymatic
immunoassay (Abbott IMX Analyzer; Abbott Park, Illinois)
(10). The coefficient of variation of this assay is 3.4% at
plasma homocystine concentrations of 7.7 to 29.1 mmol/
liter. On repeated measurement, we have been unable to
reproduce the very high homocystine levels previously re-
ported by our group, using high performance liquid chro-
matography (5). This may have been due to problems with
sample preparation, or the analytical technique itself, where
measurement of total plasma homocystine level along with
all sulfated groups may have accounted for a significant and
systematic overestimation of the true level. On reanalyzing
all samples, by the enzymatic immunoassay method, the
“high tHcy” group (top 25%) had levels of 10.5 6 3.0 mmol/
liter and the “low tHcy” group had levels of 8.5 6 1.1 mmol/
liter, and there remains a significant difference between
groups (p , 0.05) (11). Therefore, the current study still
enrolled a group of relatively HHC subjects, from our
population.
Endothelial function of the brachial artery was studied at
baseline using high resolution ultrasound, as described
previously (5,9). In brief, the diameter of the brachial artery
was measured on B-mode ultrasound images, using a
(median frequency, 7.5 MHz) linear array transducer (L
10-5) and a standard Advanced Technology Laboratories
3000 system. Scans were acquired at rest, during posttour-
niquet reactive hyperemia (to induce endothelium-
dependent dilation, EDD) and after sublingual glyceryl-
trinitrate (GTN, an endothelium-independent dilator).
EDD is predominantly due to endothelial nitric oxide
release (12), and endothelial responses of the brachial artery
measured by this method correlate significantly well with
both coronary endothelial function in the same subjects (13)
and with the extent of coronary atherosclerosis (14). The
accuracy, reproducibility and low interobserver error for this
measurement of arterial physiology have been demonstrated
previously (9).
Statistical analysis. Descriptive data are expressed as
mean 6 SD. The primary study end point was the com-
parison between EDD on folic acid or on placebo; this was
performed using the paired Student t test. Other outcome
variables after folic acid or placebo were also compared using
the Student t test, adjusted for multiple comparisons (15).
Determinants of the folic acid-related improvement in
EDD (calculated for each subject) were explored by stan-
dard univariate and multivariate regression analyses, with
age, gender, degree of reactive hyperemia, vessel size, total
cholesterol and change in serum folate and homocystine
levels as the independent variables. Statistical significance
was inferred at a two-tailed p value ,0.05.
RESULTS
All 17 subjects completed the crossover protocol. No ad-
verse events were reported, and tablet counts revealed .90%
compliance with all study medications in each case.
Subjects were aged 54 6 10 (41 to 69) years; 15 were
male and 2 were regular smokers. At baseline, the fasting
tHcy measured was 9.8 6 2.8 (8 to 20) mmol/liter, total
cholesterol was 5.7 6 0.8 (3.6 to 6.7) mmol/liter, mean
serum folate level was 34.4 6 10.4 nmol/liter, and glucose,
creatinine and vitamin B12 levels were within normal limits
in all subjects. EDD (percentage increase in brachial artery
diameter) was 5.7 6 1.2%, and GTN-induced dilation was
17.8 6 5.0%.
Compared with placebo, folic acid supplementation re-
sulted in a higher serum folate level (66.2 6 7 after folate vs
29.7 6 14.8 nmol/liter after placebo, p , 0.001), lower
tHcy levels (8.1 6 3 vs. 9.5 6 2.5 mmol/liter, p 5 0.03), but
no significant changes in cholesterol or vitamin B12 levels
(p . 0.10) (Table 1). There was a significant improvement
(relative increase of 36.7 6 21.8%) in EDD after folic acid
Abbreviations and Acronyms
EDD 5 endothelium-dependent dilation
GTN 5 glyceryltrinitrate (nitroglycerin)
Hcy 5 homocystine
HHC 5 hyperhomocystinemia
tHcy 5 total plasma homocystine
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(8.2 6 1.6% vs. 6 6 1.3% with placebo, mean absolute
difference 2.2 6 1.3%, p , 0.001) (Fig. 1). There was no
significant change, however, in the GTN response (18 6
2.4% vs. 16.6 6 2.9%, p 5 0.30). These data are consistent
with improved endothelial function after folic acid supple-
mentation.
On regression analyses, the folic acid-related improve-
ment in EDD was not associated with subject age, gender,
vessel size, degree of reactive hyperemia or serum total
cholesterol, but associated marginally with changes in tHcy
(r 5 20.35, p 5 0.17) and folate levels (r 5 0.39, p 5 0.12).
DISCUSSION
A large number of epidemiologic studies have now identi-
fied HHC as a common and independent risk factor for
premature vascular events (1,2). Cellular, experimental an-
imal and human studies have recently implicated endothelial
injury as a key early event in Hcy-related arterial disease
(3–5). For example, we have previously documented im-
paired endothelial function in children with homozygous
homocystinuria (16) and in adults in the highest quartile
range of homocystine levels within our population (5,11).
The relationship of hyperhomocystinemia and endothelial
dysfunction has been reported to be concentration-
dependent and present even at physiologic levels of homo-
cystine (7). This may be due to the chemical effects of the
free thiol group on Hcy, interacting with nitric oxide or
reducing disulfide bonds in endothelial cell molecules
(3,17), and/or due to the local generation of reactive oxygen
species (18). The pathophysiologic consequences of such
endothelial injury may include impaired release of nitric
oxide by the vessel wall (3), with significant alterations in
arterial reactivity and abnormal interactions among the
vessel wall, platelets and leukocytes (19). All of these
vascular changes associated with arterial endothelial dys-
function are known to be important events in atherogenesis
(8).
Homocysteine, folate and arterial endothelial function.
Recent studies have demonstrated that oral folic acid in a
daily dose of 1 to 10 mg consistently reduces Hcy levels by
10 to 20% (19–21). As Hcy itself has toxic effects on arterial
endothelial cells, and folic acid has an excellent safety
profile, this agent may therefore have therapeutic applica-
tions in lowering vascular risk in subjects with HHC. In this
study, we now demonstrate that folic acid supplementation
improves nitric oxide-mediated arterial endothelial function
Table 1. Biochemical Parameters and Vascular Study Results at Baseline, After Eight Weeks of






Folate (nmol/liter) 34.4 6 10.4 29.7 6 14.8 66.2 6 7.0 , 0.001
tHcy (mmol/liter) 9.8 6 2.8 9.5 6 2.5 8.1 6 3.0 0.03
Vitamin B12 (pmol/liter) 372.1 6 168.8 422.6 6 183.3 391.7 6 148.5 0.64
Cholesterol (mmol/liter) 5.7 6 0.8 5.4 6 1.0 5.4 6 0.8 0.90
Vessel size (mm) 4.1 6 0.6 4.1 6 0.6 4.1 6 0.6 0.90
EDD (%) 5.7 6 1.2 6.0 6 1.3 8.2 6 1.6 , 0.001
GTN (%) 17.8 6 5.0 16.6 6 2.9 18.0 6 2.4 0.30
Hyperemia (%) 618 6 503 772 6 402 752 6 403 0.90
*Comparing the postplacebo and postfolic acid results: see “Methods” section.
B-12 5 Vitamin B-12; EDD 5 endothelium-dependent dilation; GTN 5 glyceryltrinitrate-induced dilation; tHcy 5 total
plasma homocyst(e)ine.
Figure 1. EDD at baseline and after eight weeks of therapy with either oral folic acid, 10 mg/day (left panel) or placebo (right panel).
For each condition, the mean and SD for the group are presented.
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in healthy adults with relatively high levels of Hcy (for the
population studied). After eight weeks of oral folic acid,
average EDD improved from 6 6 1.3% to 8.2 6 1.6%
(36.7 6 21.8% relative improvement) (whereas average
EDD in control subjects from our population with lower
range tHcy levels is 10.8 6 1.7%) (5). Folic acid supple-
mentation for a brief period of 8 weeks was associated with
15% lowering of Hcy level, which conforms to the responses
previously reported, but may be underestimating the poten-
tial achievable after more prolonged supplementation. The
mechanism whereby folic acid improves arterial EDD is
uncertain. It could be due to reduction of Hcy levels,
elevation of folate levels or another mechanism (20–22).
We have observed a trend of association between changes in
Hcy levels and improvement in EDD, which was not
statistically significant however, possibly due to the rela-
tively small sample size. An alternative explanation for
improved arterial endothelial function is an independent
vascular effect of folic acid, as suggested by a recent report
demonstrating that 5-methyltetrahydrofolate (an active
form of folic acid) restored endothelial function in familial
hypercholesterolemia (23). However, to our knowledge,
there have been no data on folate supplementation given to
hypercholesterolemic, smoking patients with low Hcy lev-
els.
Studies of reversibility of endothelial dysfunction. In the
current study, we have investigated endothelial function in
the brachial artery using high resolution vascular ultrasound,
an accurate and reproducible test (9) that relates mainly to
endothelial nitric oxide release in response to shear stress
(12). Endothelial function in the brachial artery correlates
significantly with that in the coronary vasculature (13) as
well as with the extent of coronary disease assessed angio-
graphically (14). As this method is noninvasive, we and
others have reported the effects of certain interventions on
serial measurements of endothelial function, both in the
setting of primary prevention (for example, the use of
L-arginine to improve EDD in asymptomatic hypercholes-
terolemic young adults) (24) and in secondary prevention
(for example, vitamin C in patients with established coro-
nary disease) (25). In the case of cholesterol lowering, there
is evidence that this therapy improves both brachial and
coronary endothelial function as well as cardiovascular
outcomes (26–28). The recent demonstration that coronary
endothelial function testing may have prognostic value (29)
suggests that interventions that improve EDD may have
clinical relevance, and this possibility awaits further pro-
spective study. On the basis of our current observation that
oral folic acid both lowers homocysteine levels in relatively
HHC subjects and improves EDD, clinical trials of this
well-tolerated therapy may be indicated.
Study limitations. The current findings of improved arte-
rial endothelial function after oral folic acid (10 mg/d) may
be applicable only to asymptomatic subjects with higher
range baseline Hcy levels, and may not necessarily be seen in
patients with HHC in the setting of coronary artery disease
or in subjects with low homocystine levels. It is also possible
that lower doses of folic acid might result in similar benefit;
however, the daily 10-mg dose of folic acid used in this trial
was well tolerated by all subjects and not associated with any
adverse events. Further studies will be required to assess if
the improved endothelial function will be sustained for
periods longer than eight weeks, or whether this arterial
improvement will translate into a decrease in clinical event
rates in subjects with HHC. As the beneficial effects on
endothelial function were no longer present 12 weeks after
treatment cessation (in those receiving folic acid then
placebo, and in whom the folate levels had returned to
baseline values), this suggests that it may be necessary to
continue long-term supplementation to maintain the ob-
served significant improvement in vascular physiology.
CONCLUSIONS
An emerging literature suggests an important link among
HHC, arterial endothelial dysfunction and premature vas-
cular events. Given the high prevalence of atherosclerosis in
developed nations, strategies for intervention in this se-
quence of arterial damage may have important public health
implications. By lowering homocystine levels and improving
arterial endothelial function in humans, oral folic acid may
have therapeutic potential as a vascular protective agent, in
HHC subjects.
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